Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Gentian Diagnostics AS's Debt-to-EBITDA or its related term are showing as below:
OSL:GENT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2609.8 Med: -0.2 Max: 1.79
Current: 1.79
During the past 13 years, the highest Debt-to-EBITDA Ratio of Gentian Diagnostics AS was 1.79. The lowest was -2609.80. And the median was -0.20.
OSL:GENT's Debt-to-EBITDA is ranked worse than 53.52% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs OSL:GENT: 1.79
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Gentian Diagnostics AS Debt-to-EBITDA Related Terms
Gentian Diagnostics AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:GENT vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Gentian Diagnostics AS (OSL:GENT) has a Debt-to-EBITDA of 0.43 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gentian Diagnostics AS. According to the industry distribution chart, Gentian Diagnostics AS ranks #251 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 53.5%.
Is Gentian Diagnostics AS's Debt-to-EBITDA too high?
Gentian Diagnostics AS's current Debt-to-EBITDA is 0.43. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. Gentian Diagnostics AS's value of 0.43 is 73.5% below this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #251 out of 469 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #251 out of 469 companies for Debt-to-EBITDA. This places Gentian Diagnostics AS in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. Gentian Diagnostics AS's value of 0.43 is 73.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Debt-to-EBITDA of 0.43 is 73.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gentian Diagnostics AS. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Debt-to-EBITDA is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.46, compared to a current price of kr40.80 — trading 31.4% below its estimated fair value. The current Debt-to-EBITDA is 0.43 and 73.5% below the Medical Devices & Instruments industry median of 1.62. Gentian Diagnostics AS's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Debt-to-EBITDA is 0.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr40.80 is trading 31.4% below its estimated GF Value™ of kr59.46.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
Debt-to-EBITDA: 0.43
GF Value™: kr59.46 vs. price of kr40.80 (31.4% below fair value)
Industry Position: 73.5% below the Medical Devices & Instruments median (#251 of 469)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
77GF Score
Get the complete analysis for OSL:GENT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
